```html

Immune Thrombocytopenic Purpura (ITP)

Overview

Immune thrombocytopenic purpura (ITP) is an autoimmune blood disorder in which the immune system mistakenly attacks and destroys platelets—the cells that help blood clot. This results in a low platelet count (thrombocytopenia) and a tendency to bleed or bruise easily.

ITP can be classified as:

• Primary (idiopathic) ITP – no underlying cause identified.
• Secondary ITP – associated with another condition such as a viral infection, autoimmune disease, or certain medications.

Although ITP can affect individuals of any age, it shows a bimodal distribution:

• Children (especially ages 2‑5) often develop acute ITP after a viral illness; many recover spontaneously.
• Adults (most commonly ages 20‑50) tend to have chronic ITP that may persist for years.

According to the CDC and NIH, the estimated prevalence in the United States is about 1–5 per 100,000 people, with a slightly higher incidence in women (approximately 60% of adult cases).

Symptoms

Symptoms stem from low platelet numbers and can vary from mild to severe. The following list covers the most common presentations:

Bleeding‑related symptoms

• Petechiae – tiny red or purple spots on the skin, often on the lower legs.
• Purpura – larger purple bruises without a clear injury.
• Epinechia (nosebleeds) – spontaneous or prolonged.
• Bleeding gums – especially after brushing teeth.
• Heavy menstrual bleeding (menorrhagia) – common in women of reproductive age.
• Gastrointestinal bleeding – may appear as black tarry stools (melena) or bright red blood.
• Hematuria – blood in the urine.
• Intracranial hemorrhage – rare but life‑threatening; symptoms include severe headache, vomiting, confusion, or loss of consciousness.

Non‑bleeding symptoms

• Fatigue or general feeling of being unwell.
• Headaches that are not related to bleeding.
• Joint or bone pain (occasionally related to medication side‑effects rather than ITP itself).

Because platelet counts can fluctuate, symptoms may wax and wane. Some patients notice bruising after minor bumps that would not normally cause a bruise.

Causes and Risk Factors

ITP is primarily an autoimmune process. The body creates antibodies that bind to platelets, marking them for destruction by the spleen and liver. The exact trigger for antibody production is often unclear, but several factors have been identified:

Potential triggers

• Infections – especially viral (e.g., Epstein‑Barr virus, HIV, hepatitis C, Helicobacter pylori). In children, many cases follow a mild respiratory or gastrointestinal infection.
• Medications – certain drugs (e.g., quinine, sulfonamides, heparin, some antibiotics) can induce an immune response against platelets.
• Vaccinations – rare reports of ITP after measles‑mumps‑rubella (MMR) or COVID‑19 vaccines; benefits of immunization far outweigh the risk.
• Autoimmune diseases – systemic lupus erythematosus, rheumatoid arthritis, and autoimmune thyroid disease are linked with secondary ITP.
• Lymphoproliferative disorders – such as chronic lymphocytic leukemia or lymphoma.

Risk factors

• Female sex (particularly in adults).
• History of another autoimmune condition.
• Recent viral infection or exposure to certain drugs.
• Genetic predisposition is not well defined, but family clustering has been reported.

Diagnosis

Diagnosing ITP is essentially a process of exclusion – ruling out other causes of low platelets. A typical work‑up includes:

1. Medical history & physical exam

• Ask about recent infections, medication use, bleeding symptoms, and family history of autoimmune disease.
• Physical exam focuses on skin findings (petechiae, purpura), mucosal bleeding, and spleen size.

2. Laboratory tests

• Complete blood count (CBC) with peripheral smear – shows isolated thrombocytopenia; red and white cells are usually normal.
• Platelet antibody testing – not routinely required because of limited sensitivity.
• Coagulation profile (PT/INR, aPTT) – typically normal, helping differentiate from disseminated intravascular coagulation.
• Liver function tests, hepatitis B/C serology, HIV test – to rule out secondary causes.
• Helicobacter pylori stool antigen or breath test – especially in adults with chronic ITP.

3. Bone marrow examination

Reserved for patients with atypical features (e.g., age >60 with additional cytopenias, abnormal smear). In ITP, marrow usually shows normal or increased megakaryocytes, indicating platelet production is intact.

4. Imaging

Ultrasound or CT may be used if splenomegaly or lymphoproliferative disease is suspected.

Treatment Options

Therapy aims to raise platelet counts to a safe level (usually >30,000‑50,000/µL) and prevent serious bleeding. Treatment decisions depend on platelet count, bleeding severity, patient age, comorbidities, and personal preference.

First‑line therapies

• Corticosteroids (e.g., prednisone 1 mg/kg daily) – reduce antibody production. Tapered over weeks to months.
• Intravenous immune globulin (IVIG) – rapid, short‑term rise in platelets useful for severe bleeding or pre‑operative preparation.
• Anti‑D immunoglobulin (for Rh‑positive patients) – works similarly to IVIG but less commonly used.

Second‑line / chronic management

• Rituximab – anti‑CD20 monoclonal antibody; induces long‑term remission in ~40‑60% of patients.
• Thrombopoietin receptor agonists (TPO‑RAs) – eltrombopag, romiplostim, and avatrombopag stimulate platelet production. Effective in >70% of refractory cases.
• Splenectomy – surgical removal of the spleen; historically the most durable cure (60‑70% remission) but carries infection risk.
• Immunosuppressants (e.g., azathioprine, mycophenolate, cyclophosphamide) – considered when other agents fail.

Adjunctive measures

• Tranexamic acid – antifibrinolytic; helpful for mucosal bleeding.
• Platelet transfusion – reserved for life‑threatening hemorrhage or before surgery; transfused platelets are rapidly destroyed but can provide a temporary bridge.
• Vaccinations – especially pneumococcal, meningococcal, and Haemophilus influenzae type b if splenectomy is performed.

Lifestyle and supportive care

• Avoid medications that impair platelet function (aspirin, NSAIDs, anticoagulants) unless prescribed.
• Use a soft toothbrush and electric razor to reduce gum or skin trauma.
• Wear protective gear during contact sports.
• Maintain a balanced diet rich in iron, vitamin B12, and folate to support overall hematopoiesis.

Living with Immune Thrombocytopenic Purpura

Chronic ITP can be emotionally taxing. Here are practical strategies to help maintain quality of life:

• Regular monitoring – schedule CBC checks every 1‑3 months (more often after medication changes).
• Medication diary – record doses, side‑effects, and platelet trends to discuss with your hematologist.
• Support networks – consider joining ITP patient groups (e.g., ITP connection, American Society of Hematology patient forums).
• Stress management – chronic illness can increase cortisol, which may affect immunity. Techniques such as mindfulness, yoga, or counseling are beneficial.
• Travel precautions – carry a letter from your physician explaining the diagnosis, medications, and the need for a possible platelet transfusion.
• Pregnancy planning – ITP can affect pregnancy; work closely with a maternal‑fetal medicine specialist. Most women have successful pregnancies, but platelet counts may need closer monitoring.

Prevention

Because ITP is largely autoimmune, there is no guaranteed way to prevent it. However, risk can be minimized:

• Prompt treatment of underlying infections (e.g., H. pylori eradication) has been shown to improve platelet counts in some adults.
• Discuss medication histories with physicians; avoid drugs known to trigger thrombocytopenia when alternatives exist.
• Stay up‑to‑date with vaccinations; while rare, vaccine‑associated ITP is generally mild and resolves quickly.
• Adopt a healthy lifestyle (balanced diet, regular exercise, adequate sleep) to support a well‑functioning immune system.

Complications

If left uncontrolled, low platelets can lead to serious health issues:

• Severe bleeding – intracranial hemorrhage, gastrointestinal bleeding, or massive epistaxis.
• Iron‑deficiency anemia – from chronic occult GI bleeding.
• Infections – especially after splenectomy or if immunosuppressive therapy is used.
• Medication toxicity – long‑term steroids cause osteoporosis, diabetes, cataracts, and hypertension.
• Psychological impact – anxiety, depression, and reduced quality of life are common in chronic ITP patients.

When to Seek Emergency Care

---

References:

• Mayo Clinic. “Immune thrombocytopenic purpura (ITP).” Updated 2023.
• Centers for Disease Control and Prevention (CDC). “Thrombocytopenia.” 2022.
• National Institutes of Health (NIH) – National Heart, Lung, and Blood Institute. “ITP Clinical Guidelines.” 2021.
• Cleveland Clinic. “Immune Thrombocytopenic Purpura (ITP) Treatment.” 2023.
• World Health Organization (WHO). “Basic Hematology.” 2020.
• Provan D, et al. “International Consensus Report on the Investigation and Management of Primary Immune Thrombocytopenia.” *Lancet Haematology*, 2022.

```